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Objectives. To determine the potential of lipid-lowering therapy 
to reduce saphenous vein graft obstruction, we retrospectively 
studied the association between graft obstruction and serum 
cholesterol levels. 
Background. Atherosclerosis is the major cause of vein graft 
obstruction. Approximately 50% of grafts are occluded by 10 years 
after operation. It remains to be established whether lipid control 
affects long-term graft survival. 
Methods. We carried out a retrospective review of all 284 
patients who had undergone coronary artery bypass graft surgery 
at Juntendo University Hospital between 1976 and 1991 and met 
the following additional criteria: at least one saphenous vein graft, 
repeat coronary arteriography at some point after coronary artery 
bypass graft surgery and a serum cholesterol level >200 mg/dl 
before operation. Saphenous vein graft obstruction rates were 
compared among three groups classified by serum cholesterol 
levels at follow-up arteriography: group I <200 mg/dl; group II 
200 to 239 mg/di; group III >240 mg/dl. A vein graft was 
considered obstructed if it was narrowed by ->70%. 
Results. In group I, 88% of grafts were not obstructed 7 years 
after operation. The respective rates were 61% in group II and 
57% in group III (p < 0.005). This relation was true for vein grafts 
to the left anterior descending and other coronary arteries. 
Conclusions. Lower serum cholesterol levels are associated with 
lower rates of vein graft obstruction for up to 7 years. This 
suggests that cholesterol-lowering therapy may improve long-term 
saphenous vein graft survival after coronary artery bypass sur- 
gery. 
(JAm CoU Cardioi 1995;25:193-7) 
Atherosclerosis progressively obstructs aortocoronary vein 
grafts and occludes -50% of grafts within 10 years of opera- 
tion (1-3). Saphenous vein graft occlusion is associated with 
recurrence of angina, acute myocardial infarction and death 
(4,5). Compared with vein grafts, arterial conduits uch as the 
internal mammary artery demonstrate better long-term pa- 
tency and have therefore come into common use for coronary 
artery bypass urgery (6-9). However, the saphenous vein graft 
is still frequently used for vessels other than the left anterior 
descending coronary artery and must be used in patients for 
whom an arterial conduit is not available (10,11). 
The occurrence of graft atherosclerosis is related to the 
plasma lipoprotein levels. Campeau et al. (3) demonstrated 
that the high plasma levels of very low density lipoprotein 
(VLDL) and low density lipoprotein (LDL) and low levels of 
high density lipoprotein (HDL) were associated with the 
appearance of new disease in both saphenous vein grafts and 
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native coronary arteries. Although there have been many 
cholesterol-lowering trials focused on the native coronary 
arteries, only one (the Cholesterol Lowering Atherosclerosis 
Study [CI_AS] [12,13]) has studied patients with coronary 
artery bypass graft surgery. The CLAS study suggested that 
cholesterol-lowering therapy could reduce the development of 
new lesions in saphenous vein grafts as well as the formation of 
new atheroma or progressive disease in native coronary arter- 
ies. However, follow-up was limited to 48 months, so the effects 
of cholesterol-lowering therapy for a longer period is still un- 
known. The treatment effect in native coronary arteries was 
greater at 4 years (CLAS II) than at 2 years (CLAS I). In bypass 
grafts, the only treatment effect was the prevention ofnew lesions. 
Cholesterol control did not prevent new closure or progression of 
disease in saphenous vein grafts at either 4 or 2 years. 
To determine whether lipid-lowering therapy has the potential 
to affect obstruction rates of the saphenous vein grafts for >5 
years, we retrospectively studied the saphenous vein grafts and 
serum cholesterol levels in a group of patients with coronary 
artery bypass grafts and follow-up coronary arteriography. 
Methods  
Patient selection. This study was a retrospective analysis of 
the records of certain patients who were treated at Juntendo 
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University. Patients from the Juntendo University cardiac 
catheterization laboratory data base were considered eligible 
for this analysis if they 1) had undergone lective coronary 
artery bypass graft surgery at Juntendo University Hospital 
with at least one saphenous vein graft as a conduit; 2) had 
undergone coronary arteriography at some point after opera- 
tion; and 3) had a serum cholesterol level ->200 mg/dl before 
operation. 
Laboratory tests. A fasting blood sample was taken for 
measurement of total cholesterol at the time of admission for 
coronary artery bypass graft surgery. Total cholesterol, HDL 
cholesterol and triglyceride concentrations were measured at 
the time of follow-up coronary arteriography. 
Coronary arteriography. Coronary arteriography was per- 
formed by means of the brachial or femoral artery approach. 
The cineangiogram was taken from multiple projections, and 
vein grafts were analyzed for stenosis by an experienced 
angiographer who assessed the lesion with a caliper from the 
projection that showed the most severe stenosis. Saphenous 
vein grafts were considered obstructed if the graft showed 
>70% narrowing in vessel diameter. The observer was not 
aware of the patient's erum cholesterol level. 
Statistical analysis. The chi-square test was used to com- 
pare categoric variables. Analysis of variance was used to test 
continuous variables for statistical significance. The saphenous 
vein graft obstruction rate was calculated using the Kaplan- 
Meier product limit method. The log-rank test was used to 
compare obstruction rates among the groups. The Cox propor- 
tional hazards model was used for multivariate analysis; p < 
0.05 was considered significant. 
Resu l ts  
Patient characteristics. Between 1976 and 1991, 284 pa- 
tients met the eligibility criteria and included 19.3% of the 
1,473 patients who underwent coronary bypass surgery in 
Juntendo University Hospital during the study period. To 
analyze the relation of saphenous vein graft obstruction to 
serum cholesterol evels, the following three groups were 
classified at follow-up coronary arteriography: total cholesterol 
<200 mg/dl (group I), 200 to 239 mg/dl (group II) and 
->240 mg/dl (group 1II). There were no differences among the 
three groups in mean age, number of diseased vessels, number 
of grafts and follow-up interval, although there was some 
gender difference among the groups (Table 1). The average 
time from operation to follow-up arteriography was 34 _+ 36 
months (range 1 to 168) in group I, 28 _+ 31 months (range 2 
to 124) in group II and 34 _+ 38 months (range 1 to 171) in 
group III. In group III, 39% of the patients had recurrent 
angina. The respective figures were 25% of the patients in 
group I and 31% of those in group II (p = NS). Acute 
myocardial infarction was the reason for follow-up arteriogra- 
phy in three patients (4%) in group I, four patients (3%) in 
group II and three patients (3%) in group III. Use of lipid- 
lowering agents was limited to 5% to 16% of patients in each 
Table 1. Patient Characteristics 
Group I Group II Group III 
(n - 81) (n = 117) (n = 86) 
Age (yr) 58 _+ 9 57 _+ 8 56 + 9 
Gender (F/M)* 7/74 4/113 14/72 
No. of diseased vessels 2.4 _+ 0.7 2.2 _+ 0.7 2.4 ± 0.7 
No. of grafts 2.1 _+ 0.8 2.0 +_ 0.7 2.1 ± 0.8 
Follow-up interval (too) 34 _+ 36 28 _+ 31 34 _+ 38 
Recurrence of angina (%) 20 (25) 36 (31) 33 (39) 
Use of lipid-lowering a ents (%)* 13 (16) 6 (5) 13 (15) 
Use of antiplatelet agents (%) 65 (80) 105 (90) 76 (88) 
*p < 0.05. Data presented are number (%) of patients or mean value + SD. 
F - female; M = male. 
group, and antiplatelet agents were used in 80% to 90% of the 
patients. 
Risk factors at follow-up arteriography. Serum total cho- 
lesterol evels differed significantly among the groups (Table 
2). Mean total cholesterol levels before operation were 230 _+ 
22 mg/dl in group I, 238 +_ 28 mg/dl in group II and 277 + 50 
mg/dl in group III, whereas at the time of follow-up arteriog- 
raphy, mean serum cholesterol levels were 178 _+ 18, 218 + 12 
and 274 _+ 31 mg/dl, respectively. Mean LDL cholesterol levels 
at the time of follow-up arteriography were significantly dif- 
ferent among the groups and were 108 _+ 20, 143 _ 18 and 
189 _+ 36 mg/dl, respectively. Mean triglyceride l vels were also 
significantly different among the groups. Mean levels of HDL 
cholesterol, prevalence of hypertension, prevalence of diabetes 
mellitus, prevalence of family history of coronary artery disease 
and mean body mass index were not significantly different 
among the groups. There was a trend toward a lower preva- 
lence of smoking in group I compared with group IlL 
Cumulative rate of saphenous vein grafts remaining free of 
obstruction. Allgrafts. For group I, the proportion of nonob- 
structed grafts was 94% at 1 year and 88% at 7 years after 
operation in group I (Fig. 1). The respective rates for group II 
were 93% and 61%. For group III, the rates were 94% at 1 year 
and 57% at 7 years. The obstruction rates were significantly 
lower for group I than for either group II or III (p < 0.005). 
Table 2. Risk Factors at Follow-Up Arteriography 
Group I Group II Group III 
Total cholesterol (mg/dl) 
Before bypass* 230 _+ 22 238 -+ 28 277 -+ 50 
At arteriography* 178 _+ 18 218 -+ 12 274 -+ 31 
LDL cholesterol (mg/dl)*t 108 +_ 20 143 -+ 18 189 _+ 36 
HDL cholesterol (mg/dl)t 41 ± 13 42 -+ 14 43 -+ 13 
Triglycerides (mg/dl)*t 143 _+ 66 168 ± 76 212 -+ 137 
Current smoker (%) 7 (9) 22 (19) 19 (22) 
History of hypertension (%) 24 (30) 32 (27) 28 (33) 
Diabetes mellitus (%) 16 (20) 23 (20) 25 (29) 
Family history of CAD (%) 20 (25) 32 (27) 20 (23) 
Body mass index (kg/m z) 23.5 _+ 2.6 23.8 + 3.7 23.6 ± 2 
*p < 0.0001. tAt follow-up arteriography. Data presented are number (%) 
of patients or mean value _+ SD. CAD = coronary artery disease; HDL = high 
density lipoprotein; LDL = low density lipoprotein. 
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Figure 1. Saphenous vein graft survival by cholesterol (Chol) level; 
grafts to all coronary arteries. In patients whose serum cholesterol 
levels were <200 mg/dl, the graft survival rate was significantly better 
than the rates in patients whose serum cholesterol levels were 200 to 
239 or ->240 mg/dl (p < 0.005). 
Grafts to the left anterior descending coronary artery. For 
group I at 1 year, 96% of the saphenous vein grafts to the left 
anterior descending coronary artery were free of obstruction. 
The rate at 7 years was 92% (Fig. 2). The rate was significantly 
better than that of group II: 91% nonobstructed at 1 year and 
65% nonobstructed at 7 years after operation (p < 0.05). In 
group III, the 90% of the saphenous vein grafts to the left 
anterior descending artery were nonobstructed at 1 year, and 
61% were nonobstructed at 7 years. 
Grafts to other than the left anterior descending coronary 
artery. Among the saphenous vein grafts to other than the left 
anterior descending artery in group I, 93% were nonobstructed 
at 1 year, and 86% were nonobstructed at 7 years (Fig. 3). 
These rates were significantly better than the proportion in 
Figure 2. Saphenous vein graft survival by cholesterol (Chol) level; 
grafts to left anterior descending coronary arteries. In patients whose 
serum cholesterol levels were <200 mg/dl, the graft survival rate was 
significantly better than that in patients whose serum cholesterol levels 
were 200 to 239 mg/dl (p < 0.05). 
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Figure 3. Saphenous vein graft survival by cholesterol (Chol) level; 
grafts to arteries other than the left anterior descending coronary 
artery. In patients whose serum cholesterol levels were <200 mg/dl, 
the graft survival rate was significantly better than that in patients 
whose serum cholesterol levels were ->240 mg/dl (p < 0.05). 
group III: 94% at 1 year and 59% at 7 years (p < 0.05). The 
proportion free of obstruction in group II was 94% at 1 year 
and 54% at 7 years. 
Multivariate analysis. In the multivariate analysis using 
the Cox proportional hazards model, serum total cholesterol 
was the only significant independent risk factor for graft 
obstruction. Advanced age and smoking were weakly related to 
graft obstruction. There was a tendency of negative association 
between use of lipid-lowering agents and graft obstruction 
(Table 3). 
D iscuss ion  
This study analyzed the association between saphenous vein 
graft obstruction and serum cholesterol levels at the time of 
Table 3. Factors Related to Bypass Graft Obstruction: Cox 
Proportional Hazards Model 
Variable t Value p Value 
Age 1.653 0.099 
Gender 0.741 0.459 
No. of diseased vessels -0.674 0.501 
Use of lipid-lowering - 1.728 0.085 
agents 
Use of antiplatelet agents -0.447 0.655 
Total cholesterol 2.341 0.019 
HDL cholesterol - 1.204 0.229 
Triglycerides -0.894 0.372 
Smoking 1.883 0.060 
Hypertension 0.044 0.964 
Diabetes mellitus 0.149 0.881 
Family history of CAD -0.952 0.342 
Body mass index -0.925 0.355 
Abbreviations as in Table 2. 
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follow-up coronary arteriography. We focused on subjects 
whose serum cholesterol was ->200 mg/dl before operation to 
ensure that elevated serum cholesterol had been a risk factor 
for all of these patients. The mean length of time between 
operation and follow-up angiography was 31 months. The 
longest interval was 14 years. We found that lower serum 
cholesterol levels predicted a lower probability of vein graft 
obstruction. 
Limitations of the study. This study was a retrospective 
analysis of patients who were referred for angiography for 
miscellaneous reasons, and only a small proportion of all 
surgical patients met the study criteria. Therefore, the ob- 
served obstruction rates cannot be extrapolated to the entire 
population of surgical patients. However, the association be- 
tween serum cholesterol and vein graft obstruction should be 
valid because the way in which the patients were selected for 
repeat angiography would not be expected to create aspurious 
association between serum cholesterol and observed saphe- 
nous vein graft obstruction. The relatively short mean follow- 
up period is also a limitation. However, certain patients had as 
long as 171 months of follow-up, and Kaplan-Meier product 
limit analysis allows us to take full advantage of their experi- 
ence. 
Long-term survival of saphenous vein grafts. The long- 
term benefit of coronary bypass graft surgery is limited by 
progressive atherosclerosis both in saphenous vein grafts and 
native coronary arteries. Previous serial angiographic studies 
have shown that 60% to 80% of saphenous vein grafts are 
patent at the 5th postoperative y ar, and 45% to 60% are 
patent at the 10th postoperative y ar (1-3). Vein graft occlu- 
sion is associated with recurrent angina, acute myocardial 
infarction and death (4,5). 
Current use of saphenous vein grafts. The internal mam- 
mary artery has better long-term survival than vein grafts, and 
patient survival is also better when an arterial conduit is used 
(6-9). Although arterial conduits have frequently been used in 
recent series of coronary artery surgery, the saphenous vein is 
still an important conduit in selected patients and certain 
recipient arteries (10,11). There are also patients who cannot 
receive arterial conduits because of anatomic or physiologic 
limitations. Lefrac (10) reported that despite firm data favor- 
ing the use of the internal mammary artery, only 15% of the 
surgeons practicing in the United States elected a saphenous 
vein graft as their first choice for bypassing a coronary artery, 
and although 84% of the surgeons declared that the internal 
mammary artery was their first choice for bypassing a coronary 
artery, only 56% used it in at least hree-fourths of their bypass 
procedures. 
Serum cholesterol and saphenous vein graft obstruction. 
Saphenous vein graft atherosclerosis u ually begins 2 to 3 years 
after operation, occurs most frequently in hyperlipidemic 
patients and appears morphologically similar to the atheroscle- 
rosis observed in the native coronary arteries (12,13). The 
pathology includes predominantly smooth muscle cell prolif- 
eration with extracellular pools of proteoglycans, fibrous thick- 
ening with calcification and compound intimal plaque. The 
latter are laden with foam cells, islands of blood and plasma 
proteins. Angiographic studies have demonstrated that saphe- 
nous vein graft atherosclerosis is associated with high levels of 
total cholesterol and LDL cholesterol (3,6). Campeau et al. (3) 
demonstrated that high plasma levels of VLDL and LDL 
cholesterol, along with low levels of HDL cholesterol, were 
associated with new atherosclerosis in saphenous vein grafts or 
native coronary arteries after bypass urgery. They also found 
that among the lipoprotein indexes, HDL cholesterol and 
plasma LDL apoprotein B were the best predictors of new 
disease. In the present study, total cholesterol and LDL 
cholesterol levels were significantly associated with saphenous 
vein graft obstruction. Regrettably, we did not have data on 
apoprotein levels. This topic should be addressed in future 
studies. In our data, the protective association of HDL choles- 
terol was only marginal; this might be related to the study 
patients. 
Recently itwas suggested that cholesterol-lowering therapy 
could retard progression and induce regression of atheroscle- 
rosis in both native coronary arteries and saphenous vein grafts 
(14-19). Blankenhorn et al. (14) and Cashin-Hemphill et al. 
(15) demonstrated that treating lipid disorders produced a
significant reduction in the development of new lesions in 
bypass grafts as well as new atheroma formation and progres- 
sion of disease in native coronary arteries. In the extended 
study, there was a significant treatment effect on new lesions 
but no significant effect on the progression or new closure of 
saphenous vein grafts. There may be two explanations for the 
discrepancy between these observations and our findings. First, 
in our study patients, >80% were taking antiplatelet agents; in 
CLAS, those agents were not allowed. This might affect 
thrombotic closure in saphenous vein grafts. Second, because 
of the observational style of the present study, the lipid profiles 
at follow-up arteriography probably reflect the entire time 
course after operation. However, in CLAS, the intervention 
was started -3.3 years after operation. As Cashin-Hemphill et 
al. (15) suggested, early lipid-lowering therapy may be required 
to prevent graft closure. 
Site of saphenous vein grafts inserted. The survival of 
bypass grafts to the left anterior descending coronary artery is 
critical for patient survival (5,9). In our study, the 92% survival 
rate of saphenous vein grafts to the left anterior descending 
artery in group I at 7 years after operation has great clinical 
implications. Equally important, saphenous vein grafts to other 
than the left anterior descending artery showed lower obstruc- 
tion rates for group I patients than for the other two groups. 
This finding would be especially important in patients with 
recent coronary artery bypass urgery because saphenous vein 
grafts are often the only conduits to vessels other than the left 
anterior descending artery (11). 
Conelusions. These results suggest that cholesterol- 
lowering therapy has the potential to maintain saphenous vein 
graft survival rates of almost 90% for up to 7 years after 
coronary artery bypass urgery. Confirmation of these sugges- 
tions will require randomized clinical trials. 
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